Trial site
Brain Research Center Zwolle B.V.
Zwolle, 8025 AZ, NetherlandsNot linked to an institution yet
- 11running trials
- 14closed trials
The trials here
What the 25 trials at this site are about, from their registry records.
- Phase
- Phase 213 trials
- Phase 39 trials
- Phase 13 trials
- Status
- Completed14 trials
- Recruiting6 trials
- Active, not recruiting3 trials
- Not yet recruiting2 trials
- Lead sponsor
- Hoffmann-La Roche3 trials
- Bristol-Myers Squibb2 trials
- F. Hoffmann-La Roche AG2 trials
- Glaxosmithkline Research & Development Limited2 trials
- Merck Sharp & Dohme LLC2 trials
- and 14 more
Running trials
Recruiting
Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease
NCT07781644· Phase 2· Hoffmann-La Roche· Source
Recruiting
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
NCT07770841· Phase 3· Novo Nordisk A/S· Source
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease
NCT07328451· Phase 1· Denali Therapeutics Inc.· Source
Active, not recruiting
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07170150· Phase 3· Hoffmann-La Roche· Source
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· Phase 3· Boehringer Ingelheim· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
NCT06976203· Phase 3· Bristol-Myers Squibb· Source
Recruiting
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
NCT07033494· Phase 2· Merck Sharp & Dohme LLC· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
NCT06976216· Phase 3· Bristol-Myers Squibb· Source
Recruiting
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060· Phase 3· AstraZeneca· Source
Recruiting
A study to test the biological properties of RO7568282 and whether it is safe in healthy participants and participants with Parkinson’s disease.
2024-511110-21-00· Phase 1· F. Hoffmann-La Roche AG· Source
Active, not recruiting
Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)
NCT05531526· Phase 3· AriBio Co., Ltd.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease
2024-516966-12-00· Phase 2· Novartis Pharma AG· Source
Completed
GSK4527226 Open-label Extension Study in Patients with Early Alzheimer's Disease.
2025-521107-42-00· Phase 2· Glaxosmithkline Research & Development Limited· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
NCT07174310· Phase 3· Hoffmann-La Roche· Source
Completed
A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-group Study to Evaluate the Efficacy and Safety of MK-1167 as Adjunctive Therapy in Participants with Mild to Moderate Alzheimer’s Disease Dementia
2024-515539-31-00· Phase 2· Merck Sharp & Dohme LLC· Source
Completed
EFFICACY AND SAFETY OF GSK4527226 [AL101] IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE
NCT06079190· Phase 2· Glaxosmithkline Research & Development Limited· Source
Completed
Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)
NCT06182085· Phase 2· PRInnovation GmbH· Source
Completed
Randomised, double-blind, placebo-controlled study to assess safety and efficacy of PRI-002 in patients with MCI or mild dementia due to Alzheimer’s disease (AD)
2022-503148-41-00· Phase 2· Prinnovation GmbH· Source
Completed
A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies (DLB)
2023-504373-20-00· Phase 2· Eip Pharma Inc.· Source
Completed
GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)
NCT05189210· Phase 2· GemVax & Kael· Source
Completed
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants with Early Idiopathic Parkinson’s Disease
2023-504412-14-00· Phase 1· F. Hoffmann-La Roche AG· Source
Completed
A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80
NCT05348785· Phase 2· Biogen· Source
Completed
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study with a Long-Term Extension Treatment Period to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants with Early Alzheimer’s Disease
2022-501188-42-00· Phase 2· Janssen - Cilag International· Source
Completed
A study to assess how ALZ-801 affects laboratory tests and symptoms of Alzheimer's disease in patients who have a specific genotype (APOE4).
2024-515858-25-00· Phase 2· Alzheon Inc.· Source
Active, not recruiting
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
NCT04437511· Phase 3· Eli Lilly and Company· Source
Report an error